Sponsors (18)
The bill encourages and clarifies value‑based drug purchasing to lower Medicaid costs and improve patient outcomes, but it risks higher commercial/Medicare costs, added administrative burdens, potential access harms if poorly designed, and unpredictable interactions with existing rebate and 340B rules.
State Medicaid programs and Medicaid beneficiaries stand to lower net drug costs because the bill enables and clarifies value‑based purchasing (outpatient and inpatient) and allows manufacturer payments tied to performance.
Patients — including Medicaid beneficiaries, people with chronic or rare conditions, and seniors — could gain improved access to effective therapies and better clinical outcomes if value‑based arrangements reduce barriers and align payment with results.
Manufacturers, states, and providers get greater regulatory certainty because the bill defines value‑based purchasing, aligns ASP/AMP exclusions, and requires HHS/OIG rulemaking on a 180‑day timeline — making it easier to design and adopt VBPs.
Commercial patients and taxpayers risk higher overall drug costs because manufacturers might shift pricing or reporting (or ASP exclusions could raise Medicare reimbursements), leading to higher list prices or greater federal spending.
State Medicaid agencies, hospitals, and provider systems may face substantial administrative, compliance, and implementation costs to negotiate, track, and operate complex VBPAs and inter‑state payment transfer arrangements.
Medicaid beneficiaries could suffer reduced access or perverse incentives (for example, providers or manufacturers avoiding complex patients) if value‑based payments are poorly designed or manufacturers decline participation.
Based on analysis of 6 sections of legislative text.
Enables multi-point best-price reporting and legal safe harbors to let States and manufacturers use outcome-based drug purchasing, and aligns Medicare and Medicaid payment/rebate rules to accommodate those arrangements.
Official title: To amend title XIX of the Social Security Act to codify value-based purchasing arrangements under the Medicaid program and reforms related to price reporting under such arrangements, and for other purposes.
Introduced March 9, 2026 by Brett Guthrie · Last progress March 9, 2026
Allows manufacturers and State Medicaid programs to use value-based purchasing arrangements (VBPAs) for covered outpatient drugs and aligns federal payment and rebate rules to accommodate multi-point pricing tied to outcomes. It changes how manufacturers may report multiple "best price" points for drugs sold under VBPAs, updates Medicare reimbursement calculations for certain drugs and biologics sold under VBPAs, creates an antikickback safe harbor for State VBPAs tied to patient outcomes, directs HHS to issue implementing rules and guidance within 180 days, and requires a GAO study on VBPAs' effects by June 30, 2029. The bill aims to make outcome‑based drug pricing easier to implement across Medicaid and Medicare by clarifying statutory definitions, reporting rules, payment calculations, and legal protections for transfers tied to outcomes, and by providing guidance for interstate arrangements when inpatient drugs are paid across State lines.